9/16/2011

The FDA is investigating the safety of GlaxoSmithKline's Zofran, or ondansetron, because of concern that the treatment increases the risk of abnormal heart rhythm. Zofran prevents nausea and vomiting in patients undergoing chemotherapy, surgery and radiotherapy. The FDA said it will add recommendations to Zofran's label, including electrocardiogram monitoring in certain patients.

Related Summaries